BMS-955176 explained

Legal Status:Investigational
Cas Number:1392312-45-6
Unii:4CA9IAU7RJ
Chemspiderid:58922159
C:42
H:62
N:2
O:4
S:1
Smiles:CC(=C)[C@@H]1CC[C@]2([C@H]1[C@H]3CC[C@H]4[C@]([C@@]3(CC2)C)(CC[C@@H]5[C@@]4(CC=C(C5(C)C)c6ccc(cc6)C(=O)O)C)C)NCCN7CCS(=O)(=O)CC7
Stdinchi:1S/C42H62N2O4S/c1-28(2)31-14-19-42(43-22-23-44-24-26-49(47,48)27-25-44)21-20-40(6)33(36(31)42)12-13-35-39(5)17-15-32(29-8-10-30(11-9-29)37(45)46)38(3,4)34(39)16-18-41(35,40)7/h8-11,15,31,33-36,43H,1,12-14,16-27H2,2-7H3,(H,45,46)/t31-,33+,34-,35+,36+,39-,40+,41+,42-/m0/s1
Stdinchikey:XDMUFNNPLXHNKA-ZTESCHFWSA-N

BMS-955176 is an experimental second generation HIV maturation inhibitor under development by Bristol-Myers Squibb for use in the treatment of HIV infection. By blocking the maturation of the virus, it prevents viral reproduction in host CD4+ T cells.[1] First generation maturation inhibitors such as bevirimat were ineffective against some naturally occurring changes (polymorphisms) in the Gag protease polyprotein; BMS-955176 has been designed to better tolerate gag polymorphisms.[2] [3] __TOC__

Studies

Results of a phase 2a trial of BMS-955176 was reported at the 2015 Conference on Retroviruses and Opportunistic Infections (CROI).[4] Investigators concluded that the drug was well tolerated and effective against HIV, including strains with gag polymorphisms.[5]

It appears that development of BMS-955176 has been terminated.[6]

See also

Notes and References

  1. Web site: BMS Maturation Inhibitor Is Potent Against HIV in Early Trial. 25 February 2015. 22 July 2015. https://web.archive.org/web/20150723033900/http://www.aidsmeds.com/articles/BMS_maturation_inhibitor_1667_26859.shtml. 23 July 2015. dead.
  2. Web site: CROI2015: New HIV maturation inhibitor BMS-955176 appears more potent than earlier beviramat - Project Inform.
  3. Wang D, Lu W, Li F . Pharmacological intervention of HIV-1 maturation . Acta Pharmaceutica Sinica B . 5 . 6 . 493–9 . November 2015 . 26713265 . 4675807 . 10.1016/j.apsb.2015.05.004 .
  4. Web site: Antiviral Activity/Safety of a Second-Generation HIV-1 Maturation Inhibitor CROI Conference. www.croiconference.org. 2016-01-01.
  5. Web site: HIV maturation inhibitor BMS-955176 looks promising in early study. www.aidsmap.com. 2016-01-01.
  6. Web site: GSK Discontinues Development of Maturation Inhibitor BMS-955176.

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "BMS-955176".

Except where otherwise indicated, Everything.Explained.Today is © Copyright 2009-2025, A B Cryer, All Rights Reserved. Cookie policy.